Treating hypercalcemia starts with aggressive intravenous fluid replacement and then layers on medications chosen to match the severity and underlying cause of the calcium elevation. The initial goal is straightforward: dilute the excess calcium and help the kidneys flush it out, buying time for slower-acting drugs to take effect. But beyond that first step, treatment branches significantly depending on whether cancer, overactive parathyroid glands, granulomatous disease, medications, or something else is driving the problem.
Intravenous Fluids and the Furosemide Question
The universal first move for significant hypercalcemia is pumping in normal saline, often at high volumes. Most people who present with dangerously high calcium are dehydrated, partly because high calcium itself causes the kidneys to produce more urine and partly because nausea and poor appetite reduce fluid intake. Restoring volume corrects the dehydration, improves kidney blood flow, and boosts calcium excretion in the urine. Severe cases typically require hospital admission with continuous IV fluids.1BMJ. The diagnosis and management of hypercalcaemia
For decades, loop diuretics like furosemide were added on top of IV fluids as a standard part of this initial management. The logic seemed sound: furosemide blocks calcium reabsorption in the kidney, so it should push more calcium into the urine. In practice, though, the evidence behind this approach turns out to be surprisingly thin. A critical review found that the case for furosemide in hypercalcemia rests on a handful of case reports published before bisphosphonates even existed, with no randomized controlled trials supporting the practice. The authors concluded that furosemide for hypercalcemia should no longer be routinely recommended.2PubMed. Furosemide for Hypercalcemia: An Unproven Yet Common Practice Furosemide still has a role if the patient develops fluid overload from all the IV saline, but using it specifically to lower calcium is a habit that has outlived its evidence.
Bisphosphonates as the Main Pharmacological Tool
Once fluids are running, the workhorse drugs for moderate-to-severe hypercalcemia are the bisphosphonates, which work by shutting down the cells that break down bone and release calcium into the blood. Two agents dominate: pamidronate and zoledronic acid, both given as single intravenous infusions. Zoledronic acid has largely taken the lead. In pooled data from two randomized trials, roughly half of patients treated with zoledronic acid had their calcium return to normal by day four, compared to about a third of those receiving pamidronate. The response also lasted longer: the median duration of normal calcium was 32 to 43 days with zoledronic acid versus 18 days with pamidronate.3PubMed. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials
The main drawback of bisphosphonates is speed. They take two to four days to reach their full effect, which can feel like a long time when someone’s calcium is critically high and causing confusion or heart rhythm abnormalities. That gap between starting the drug and seeing results is why clinicians often pair bisphosphonates with a faster-acting agent.
Calcitonin for Quick but Short-Lived Relief
Calcitonin, a hormone that inhibits bone breakdown and promotes calcium excretion by the kidneys, works within hours. It is given as an injection, either under the skin or into muscle, and can start lowering calcium within four to six hours. That speed makes it a useful bridge while waiting for bisphosphonates to kick in.
The catch is that calcitonin’s effect is modest and wears off fast. The body develops resistance to it, sometimes within a day or two, a phenomenon called tachyphylaxis. For this reason, many hospitals place automatic stop orders on calcitonin, limiting it to no more than two doses in 24 hours and capping the total course at about a day. A study evaluating a health system’s calcitonin-restriction policy, which reserved it for patients with symptomatic or severe hypercalcemia (corrected calcium above 13 mg/dL), found no meaningful difference in calcium reduction compared to the period when it was used more liberally.4Europe PMC / SAGE Journals. Clinical and Economic Implications of Restrictions on Calcitonin Utilization in a Health System The takeaway: calcitonin is a helpful short-term tool, not something that controls calcium on its own for more than a day.
Denosumab When Bisphosphonates Are Not Enough
Some patients, particularly those with cancer-related hypercalcemia, do not respond adequately to bisphosphonates or relapse quickly. Denosumab offers a different mechanism. Rather than coating bone surfaces the way bisphosphonates do, denosumab is an antibody that blocks a signaling protein critical for the formation and survival of bone-resorbing cells. It is given as a subcutaneous injection.
In a study of patients with bisphosphonate-refractory hypercalcemia of malignancy, about 64% achieved calcium levels at or below 11.5 mg/dL by day ten, and 70% did so at some point during the study. Among those who responded, the median duration of response was over 100 days, which is substantially longer than what bisphosphonates typically deliver.5Journal of Clinical Oncology. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM) That durability matters enormously for patients with advanced cancer who would otherwise face repeated hospital admissions for recurrent calcium spikes.
Denosumab does carry risks that require monitoring. In large trials of patients with bone metastases, about one in ten developed low calcium (hypocalcemia), though most cases were mild and resolved within a few weeks. Osteonecrosis of the jaw, a condition where jawbone tissue dies, occurred in roughly 1.8% of patients receiving denosumab over three years.6PubMed. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures Patients starting denosumab usually need calcium and vitamin D supplementation, along with regular blood monitoring and dental evaluation, to stay ahead of these complications.
When the Underlying Cause Determines the Treatment
The treatments above address the elevated calcium directly, but lasting control usually depends on tackling whatever is producing it. The cause shapes the strategy in ways that matter practically.
Granulomatous Disease and Vitamin D-Driven Hypercalcemia
In conditions like sarcoidosis and tuberculosis, immune cells produce excess active vitamin D, which ramps up calcium absorption from the gut. Corticosteroids are the treatment of choice here because they suppress the enzyme in those immune cells that generates the active form of vitamin D.7Europe PMC. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment The same mechanism can occur in certain lymphomas, where tumor cells overproduce active vitamin D. Corticosteroids work in those cases too, serving double duty by fighting both the calcium elevation and the underlying malignancy.8Europe PMC. Hypercalcemia of Malignancy: An Update on Pathogenesis and Management
For patients with rarer vitamin D-dependent forms of hypercalcemia, particularly those caused by genetic mutations that impair the body’s ability to break down active vitamin D, antifungal medications like ketoconazole and fluconazole have shown promise. These azole drugs inhibit the enzyme that activates vitamin D, effectively turning down the tap. Published case reports and small studies have documented their use in conditions ranging from infantile hypercalcemia to sarcoidosis.9Elsevier / The Clinics. Vitamin D–dependent Hypercalcemia These remain somewhat niche treatments, but they fill an important gap when corticosteroids are not enough or not appropriate.
Primary Hyperparathyroidism
When one or more overactive parathyroid glands are pumping out excess parathyroid hormone, surgery to remove the offending gland or glands is the definitive fix. Primary hyperparathyroidism is not rare, diagnosed in roughly 0.7% of the general population and about 2% of postmenopausal women in Western countries.10PubMed Central / Cancer. Surgery for primary hyperparathyroidism Parathyroidectomy cures the vast majority of cases, and guidelines recommend it for all symptomatic patients and for younger patients even without obvious symptoms.
For patients who cannot have surgery or who prefer to delay it, the calcimimetic cinacalcet offers a medical alternative. Cinacalcet works by making the calcium-sensing receptor on parathyroid cells more sensitive, tricking the glands into thinking calcium is higher than it actually is, so they dial back parathyroid hormone production. Studies have shown it can reduce parathyroid hormone levels by at least 30% while simultaneously lowering calcium and phosphorus.11PubMed. Calcimimetics and the treatment of primary and secondary hyperparathyroidism It does not cure the underlying gland problem, so calcium tends to drift back up if the drug is stopped, but it keeps things controlled in the meantime.
Drug-Induced Hypercalcemia
Certain medications can push calcium levels up as a side effect. Lithium, widely used for bipolar disorder, is one of the more common culprits. It can stimulate the parathyroid glands over time, leading to elevated parathyroid hormone and calcium. The management decision is tricky because stopping lithium may destabilize the psychiatric condition, so treatment often involves a careful discussion between endocrinologist and psychiatrist. One practical detail: thiazide diuretics, which are sometimes prescribed for other reasons in these patients, should be reconsidered because they reduce calcium excretion by the kidneys and can worsen the problem.12PubMed Central. Lithium induced hypercalcemia: an expert opinion and management algorithm Excessive vitamin D supplementation and certain cancer therapies can also cause hypercalcemia, and in those situations, stopping or adjusting the offending agent is often the most effective intervention.
Hemodialysis for Life-Threatening Cases
When calcium is dangerously high and the usual medical therapies are not working fast enough, or when the kidneys have failed and cannot excrete calcium at all, hemodialysis with a low-calcium or calcium-free bath can pull calcium directly out of the blood. A case report documented rapid improvement in consciousness and disappearance of dangerous heart rhythm changes after hemodialysis was started in a patient with extreme hypercalcemia complicated by acute kidney injury.13PubMed Central. Treatment of extreme hypercalcaemia: the role of haemodialysis
Despite its effectiveness, dialysis is rarely the first choice. It is invasive, requires specialized equipment and vascular access, and carries its own risks. A study of 33 patients treated with calcium-free hemodialysis for severe hypercalcemia concluded that after correcting dehydration with IV fluids, dialysis should be reserved for those with severe symptoms or significant kidney impairment.14PubMed. Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia It is the emergency brake rather than the steering wheel, pulled when nothing else is controlling the situation fast enough to prevent cardiac arrest or permanent neurological damage.
How Treatment Differs in Children
Pediatric hypercalcemia shares the same initial playbook as adult cases: increase fluid intake and drive calcium excretion through the kidneys. The underlying causes, however, skew differently. While cancer-related hypercalcemia dominates the adult population, children are more likely to have genetic conditions, vitamin D toxicity, or primary hyperparathyroidism. In most pediatric cases, the calcium elevation still traces back to excessive bone breakdown, so agents that inhibit bone-resorbing cells (the same bisphosphonates used in adults) are effective.15Europe PMC / Current Opinion in Pediatrics. Hypercalcemia in children and adolescents
One area where pediatric practice diverges from adult practice is surgery. Parathyroidectomy is recommended for all children diagnosed with primary hyperparathyroidism, not just those with symptoms. The rationale is that the long-term skeletal and renal consequences of unchecked parathyroid hormone are harder to justify in someone with decades of life ahead. In adults, watchful waiting with periodic monitoring is sometimes considered acceptable for mild, asymptomatic cases. That latitude is generally not extended to children.
Putting the Pieces Together in Practice
In real-world clinical practice, treatment for hypercalcemia almost always involves layering multiple approaches simultaneously rather than trying them one at a time. A typical sequence for someone admitted with severe cancer-related hypercalcemia might look like this: IV saline starts immediately, calcitonin goes in within the first few hours for a quick partial reduction, and a bisphosphonate infusion is ordered for the same day. If the calcium does not come down adequately over the next few days, denosumab enters the picture. Concurrently, the oncology team works on controlling the cancer itself, since no amount of calcium-lowering medication provides lasting control if the tumor keeps driving the process.
For someone with primary hyperparathyroidism whose calcium is only mildly elevated and who has no symptoms, the approach might be nothing more than ensuring good hydration, avoiding excessive calcium and vitamin D intake, and scheduling a parathyroidectomy. The urgency depends entirely on the numbers and the clinical picture.
Emerging and Niche Therapies
A few treatment approaches sit at the edges of current practice. In cancers that produce interleukin-6, a signaling molecule that can stimulate bone breakdown and contribute to hypercalcemia, blocking IL-6 with antibodies like siltuximab or tocilizumab has shown clinical utility. These agents are already approved for conditions like Castleman disease and cytokine release syndrome, and they can reduce the inflammatory signals that feed both the cancer and the calcium elevation.16PubMed Central. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family In multicentric Castleman disease specifically, blocking IL-6 has produced durable clinical responses.17Current Medicinal Chemistry. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities
These immunotherapy-based approaches are not standard first-line hypercalcemia treatments, but they illustrate how treating the underlying disease process can indirectly resolve the calcium problem. As targeted cancer therapies continue to evolve, the line between “treating the cancer” and “treating the hypercalcemia” is likely to blur further, with drugs that control both at once becoming more common. For now, the mainstay remains the stepwise approach of fluids, bisphosphonates, and cause-specific interventions, refined over decades and supported by a solid body of clinical trial data.